Pediatric Brain Cancer:
U.S. Phase 1 Clinical Trial
Not Yet Recruiting
Not Yet RecruitingPediatric Brain
Cancer: U.S. Phase
1 Clinical Trial
Not Yet Recruiting
Pediatric
Brain
Cancer:
U.S. Phase
1 Clinical
Trial
Not Yet Recruiting
Trial Information
Pediatric brain cancer is relatively rare. However, cancer is the leading cause of death by disease among children in the U.S. Brain and spinal cord tumors are the 2nd most common cancers in children, accounting for ~26% of childhood cancers.
Plus Therapeutics is developing the Rhenium (186Re) Obisbemeda radiotherapeutic for the treatment of rare, frequently fast-growing pediatric brain and spinal cord tumors with a poor prognosis – ependymoma and high-grade glioma (HGG). The ReSPECT-PBC (Pediatric Brain Cancer) U.S. Phase 1 Clinical Trial is planned to start in 2025.
“Children with brain tumors have limited options & 186RNL delivered with a minimally invasive procedure could be an important new potential option for these patients.”
Michael G. DeCuypere, MD, PhD, FAANS
Northwestern University Feinberg School of Medicine
Principal Investigators
There is a physician who is responsible for the scientific and technical direction of the clinical trial at each location.
Ashley S. Plant, M.D.
Lurie Children’s Hospital of Chicago
SPECIALTIES: CANCER & BLOOD DISORDERS
Ashley S. Plant, M.D. is an attending physician in neuro-oncology at Ann and Robert H. Lurie Children’s Hospital of Chicago and is an Assistant Professor of Pediatrics at Northwestern University. Dr. Plant received her medical degree from Stanford University School of Medicine. She completed her pediatrics residency at University of California, Los Angeles and her pediatric hematology/oncology fellowship at Dana Farber Cancer Institute/Boston Children’s Hospital. She completed additional training in neuro-oncology at Dana Farber Cancer Institute. Her research focus includes immunotherapy and the immune microenvironment as well as early phase clinical trial design for pediatric brain tumors.
Trial Locations
Please visit this website regularly for updates as new locations are added.
Lurie Children’s Hospital
Chicago, Illinois
What Can You Do Next?
Participating in a clinical trial is an important decision. If you believe this clinical trial might be a good fit and are interested in participating, please take the next step to see if you are eligible.
Request Information
News
November 29, 2023
Plus Therapeutics to Present at the 5th Targeted Radiopharmaceuticals Summit Europe
- Presentation titled “Re-186 Radiolabelled NanoLiposomes for Rare Brain and Spinal Cord Tumors”
June 8, 2023
- Plus Therapeutics announced it will exhibit at both the Society for NeuroOncology’s (SNO) Pediatric Conference, taking place June 22-24, 2023 in Washington, D.C., and the Society of Nuclear Medicine & Molecular Imaging’s (SNMMI) Annual Meeting, taking place June 24-27, 2023 in Chicago, Illinois.
August 21, 2021
June 10, 2021
Plus Therapeutics Presents at the Sixth Biennial Pediatric Neuro-Oncology Research Conference
Publications
Posters
Resources
Note: all external links
- American Brain Tumor Association
- American Cancer Society
- American Childhood Cancer Organization
- Brain Tumor Network
- Dictionary of Cancer Terms
- End Brain Cancer Initiative
- Ependymoma Cancer Research Network
- MedlinePlus (NIH)
- National Brain Tumor Society
- National Cancer Institute
- National Comprehensive Cancer Network
- Pediatric Brain Tumor Foundation
- Support Groups Listing
- The Brain Tumour Charity
- Trial Connect
- VirtualTrials.com
- Voices Against Brain Cancer
Updates
SpectronRx Partnership
BREAKING NEWS: Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership Partnership will expand Plus’ capability to meet late-stage clinical and commercial forecasts for Rhenium (186Re) Obisbemeda and reinforce supply chain redundancy Press...
ABTA 5K NYC
Come join us at the upcoming @the_abta 5K run in New York City! It’s not too late to register as we join together in the fight against brain cancer. Plus Therapeutics is proud to be a sponsor and will have a booth on-site to provide education about our clinical...
CNS 2024
Reminder to come by Plus Therapeutics at the @CNS_update 2024 Annual Meeting at Booth #2038 Plus Therapeutics is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the...
#WorldCancerResearchDay
Today is #WorldCancerResearchDay! Join us in celebrating the incredible advancements in cancer research and the dedicated researchers working tirelessly to find new treatments and cures. Every breakthrough brings us one step closer to a cancer-free future🔬🌟🎗️ Learn...